|
|
Antimicrob Agents Chemother. 1993 December; 37(12): 2736–2739. | PMCID: PMC192796 |
In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium. P French, E Venuti, and H S Fraimow Dorrance H. Hamilton Laboratories, Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107. Abstract Sixty strains of vancomycin- and ampicillin-resistant Enterococcus faecium were evaluated for their susceptibilities to novobiocin in vitro. In Mueller-Hinton broth, novobiocin inhibited all strains when it was used at a concentration of < or = 2 microgram/ml and 40 of 60 strains when it was used at a concentration of < or = 0.5 micrograms/ml. MICs were 8- to 16-fold higher in 50% serum. Novobiocin alone resulted in 2-log-unit killing at 24 h. Combinations of novobiocin and a fluoroquinolone (either ciprofloxacin or ofloxacin) were additive and bactericidal for quinolone-susceptible strains in either broth or 50% serum. Gentamicin did not affect novobiocin activity, and rifampin and doxycycline were antagonistic. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (668K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Arathoon EG, Hamilton JR, Hench CE, Stevens DA. Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrob Agents Chemother. 1990 Sep;34(9):1655–1659. [PubMed]
- BRIDGES RA, BERENDES H, GOOD RA. Serious reactions to novobiocin. J Pediatr. 1957 May;50(5):579–585. [PubMed]
- Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother. 1986 Jul;30(1):42–45. [PubMed]
- Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991 Jan 15;51(2):510–513. [PubMed]
- Evers S, Sahm DF, Courvalin P. The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding D-Ala:D-Ala ligases and glycopeptide-resistance proteins VanA and VanC. Gene. 1993 Feb 14;124(1):143–144. [PubMed]
- Fraimow HS, Venuti E. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1992 Jul;36(7):1563–1566. [PubMed]
- Handwerger S, Perlman DC, Altarac D, McAuliffe V. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis. 1992 Mar;14(3):655–661. [PubMed]
- Jones RN. Should novobiocin be clinically re-evaluated? Diagn Microbiol Infect Dis. 1989 Jul–Aug;12(4):363–365. [PubMed]
- Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990 Jan;3(1):46–65. [PubMed]
- NICHOLS RL, FINLAND M. Novobiocin; a limited bacteriologic and clinical study of its use in forty-five patients. Antibiotic Med Clin Ther. 1956 Apr;2(4):241–257. [PubMed]
- Rolinson GN, Sutherland R. The binding of antibiotics to serum proteins. Br J Pharmacol Chemother. 1965 Dec;25(3):638–650. [PubMed]
- Sahm DF, Koburov GT. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother. 1989 Jan;33(1):71–77. [PubMed]
- Schaberg DR, Dillon WI, Terpenning MS, Robinson KA, Bradley SF, Kauffman CA. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2533–2535. [PubMed]
- Spera RV, Jr, Farber BF. Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA. 1992 Nov 11;268(18):2563–2564. [PubMed]
- Walsh TJ, Auger F, Tatem BA, Hansen SL, Standiford HC. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin. J Antimicrob Chemother. 1986 Jan;17(1):75–82. [PubMed]
- Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, Montgomerie JZ, Goetz MB, Mayhall CG, Rimland D, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother. 1993 Jun;37(6):1334–1342. [PubMed]
- Watanabe Y, Kitayama R, Hayashi T, Nakashima Y, Noguchi M, Yasuda T, Saikawa I, Shimizu K. Studies on protein binding of antibiotics. IV. Effect of the binding of drug to 100,000 X g supernatant fluid of rabbit liver homogenates on urinary excretion. J Antibiot (Tokyo). 1982 Nov;35(11):1603–1609. [PubMed]
- WRIGHT WW, PUTNAM LE, WELCH H. Novobiocin; serum concentrations and urinary excretion following oral administration in man. Antibiotic Med Clin Ther. 1956 May;2(5):311–316. [PubMed]
|
This article has been